New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
08:11 EDTAMPEAmpio closes enrollment in OptimEyes study for presentation to FDA
Ampio Pharmaceuticals has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema - oral treatment with Optina. The present enrollment of over 355 patients provides an adequate power of 88%, which the company believes is more than sufficient for statistical evaluation. By reducing the patient sample size, the company expects data by Q4.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
07:17 EDTAMPEAmpio's Ampion for osteoarthritis shows positive top-line results
Ampio announced results of the double-blind, multiple injection, vehicle controlled STRUT study at 20 weeks. The forty patient randomized phase of the STRUT study was conducted to assure that multiple injections of Ampion were safe and effective. Each patient received three 4 mL intra-articular injections of Ampion or saline at baseline, 2 weeks and 4 weeks. There were no drug related serious adverse events. The primary endpoint that is required for FDA approval, WOMAC A pain score, improved by 64% from baseline to 20 weeks. Responder rate for Ampion was 79% compared to 47% of saline patients. Data for the larger, multi-site STRIDE study, a similar design to STRUT study, is expected in Q2.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use